top of page
_edited.jpg

BLOG

New Antipsychotic Agent Available for Bipolar Mania, Schizophrenia

Allergan has announce the availability of Vraylar (cariprazine capsules) for the acute treatment of manic or mixed episodes associated with bipolar 1 disorder and for the treatment of schizophrenia in adults.

Vraylar is an atypical antipsychotic that exerts its effect through a combination of partial agonist activity at central dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. It acts as an antagonist at 5-HT2B and 5-HT2A receptors with high and moderate binding affinity as well as it binds to the histamine H1 receptors. Cariprazine shows lower binding affinity to the serotonin 5-HT2C and alpha1A- adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors.

The FDA’s approval was based on data from three 3-week controlled trials in adults with manic or mixed episodes of bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia, which included over 2,700 adults total. Treatment with Vraylar showed improvement vs. placebo as measured by Young Mania Rating Scale (YMRS) total scores in patients with bipolar mania and by Positive and Negative Syndrome Scale (PANSS) total scores in patients with schizophrenia. Vraylar also showed efficacy as measured by the Clinical Global Impressions-Severity (CGI-S) rating scale, meeting the study’s secondary efficacy endpoints for both conditions.

Cariprazine is also being investigated for the treatment of bipolar depression, the negative symptoms of schizophrenia, and as adjunctive treatment for major depressive disorder in adults.


Senaste inlägg

Visa alla

Comments


bottom of page